Tacrolimus
Phase 2/3Completed 1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Interstitial Pneumonitis
Conditions
Interstitial Pneumonitis, Polymyositis, Dermatomyositis
Trial Timeline
Jul 1, 2007 → Jan 1, 2011
NCT ID
NCT00504348About Tacrolimus
Tacrolimus is a phase 2/3 stage product being developed by Astellas Pharma for Interstitial Pneumonitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00504348. Target conditions include Interstitial Pneumonitis, Polymyositis, Dermatomyositis.
What happened to similar drugs?
1 of 5 similar drugs in Interstitial Pneumonitis were approved
Approved (1) Terminated (2) Active (3)
✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189761 | Phase 2 | Completed |
| NCT00293930 | Phase 3 | Completed |
| NCT00189787 | Phase 2 | Completed |
| NCT00189722 | Phase 2 | Completed |
| NCT03465969 | Approved | Completed |
| NCT02555787 | Pre-clinical | Completed |
| NCT02147938 | Pre-clinical | Completed |
| NCT02143479 | Pre-clinical | Completed |
| NCT02159651 | Pre-clinical | Completed |
| NCT02057484 | Pre-clinical | Completed |
| NCT02377609 | Pre-clinical | Terminated |
| NCT01745159 | Approved | Completed |
| NCT01511003 | Approved | Completed |
| NCT01316133 | Approved | Terminated |
| NCT01410162 | Approved | Completed |
| NCT02963103 | Approved | Terminated |
| NCT01224041 | Approved | Completed |
| NCT01224418 | Approved | Completed |
| NCT00504348 | Phase 2/3 | Completed |
| NCT01410747 | Pre-clinical | Completed |
Competing Products
20 competing products in Interstitial Pneumonitis